Thymosin Beta-4
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Thymosin beta-4 is a naturally occurring peptide of 43 amino acids that is present in nearly all human cells. It is best known as the primary actin-sequestering molecule in the body, meaning it helps regulate the assembly of the cellular scaffolding that drives cell movement and shape.
It is most often discussed in the context of tissue repair, where it has been studied for its apparent role in wound healing, reducing inflammation, and supporting cardiovascular tissue after injury. Much of the interest in this peptide comes from preclinical work on skin, corneal, and cardiac injury models.
TB-500, a peptide frequently referenced in recovery protocols, is commonly described as a synthetic fragment of thymosin beta-4 containing its active region. Full-length thymosin beta-4 is the complete, naturally occurring molecule.
How it works
By binding G-actin monomers, thymosin beta-4 helps control the availability of actin for filament assembly, which in turn influences cell migration — a process central to closing and remodeling wounds. In preclinical studies it has also been reported to promote angiogenesis, the formation of new blood vessels, which may support repair by improving blood flow to injured tissue.
Researchers have described additional effects on inflammatory signaling, cell survival, and the organization of collagen during healing. Several molecular pathways have been proposed, but the precise mechanisms in humans are not fully established.
Reported benefits
- Faster wound healing and improved tissue remodeling (animal data)
- Reduced inflammation at sites of injury
- Support for cardiovascular tissue repair after injury (preclinical models)
- More organized collagen and reduced scar-forming myofibroblasts in wound studies
These are reported and studied effects, not guaranteed outcomes.
Considerations & side effects
Although thymosin beta-4 is an endogenous peptide and has been evaluated in some early clinical trials, its long-term safety profile in humans is not well characterized, and it is not approved for therapeutic use. Reported side effects in research contexts are generally mild and can include injection-site irritation.
Product purity varies widely in the research-chemical market. Thymosin beta-4 is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is thymosin beta-4?
A naturally occurring 43-amino-acid peptide found in most human cells, where it is the major actin-sequestering protein. It is studied for its role in tissue repair, cell migration, and inflammation.
How is it different from TB-500?
TB-500 is commonly sold as a synthetic fragment of the thymosin beta-4 molecule that includes its active actin-binding region. Full-length thymosin beta-4 is the complete peptide, while TB-500 represents only a portion of it.
Is thymosin beta-4 FDA-approved?
No. It is not approved by the FDA or any major regulator for human therapeutic use and is sold for research purposes only, though it has been evaluated in some clinical trials.
How is it typically administered?
Most commonly by subcutaneous or intramuscular injection after reconstitution with bacteriostatic water.
References
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. ↗
- Xing Y, et al. Progress on the Function and Application of Thymosin β4. ↗
- Ehrlich HP, Hazard SW. Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts. ↗
Related compounds
Body Protection Compound-157. A pentadecapeptide derived from human gastric juice. Known for tissue healing, gut health, and injury recovery.
Pre-mixed blend of BPC-157 and TB-500, the most popular healing combination. Sold as a single combined vial from compounding pharmacies for injury recovery and tissue repair.
An arginate-salt formulation of the BPC-157 pentadecapeptide (also sold as 'PDA'). The arginine salt buffers the peptide across a wider pH range, improving stability and oral bioavailability versus the standard acetate form. Same healing uses as BPC-157.